46th Union World Conference on Lung Health

When: 2-6 December 2015

Organized by IUATLD

Where: Cape Town, South Africa

Information: http://capetown.worldlunghealth.org

The presentations:

Introduction of outpatient care for DS-/MDR-TB patients in Tajikistan

46th UNION – Strengthening specimen referral and transport networks in resource-limited settings a Nigerian pilot to improve diagnosis

Benchmarking tool Childhood TB – Vietnam experience

UNION symposium 12 managing PV systems

Meet our experts

During the Union Conference in Cape Town there was an opportunity to meet and greet some of KNCV’s most prominent experts.
Jerod Scholten, Frank Cobelens, Eveline Klinkenberg, Jeroen van Gorkom, Suzanne Verver, Michael Kimerling, Kathy Fiekert all took turns in being present at the KNCV booth.

KNCV Tuberculosis Foundation participation at the 46th Union World Conference included the following:


Thursday, 03 December 2015

Update on clinical and programmatic management of MDR- and XDR- TB         

MDR/XDR-TB global epidemiology (including the epidemiology of HIV-coinfection)
Presenter/chair: to be decided

Risk factor management and tuberculosis control
Presenters/chairs: Kitty van Weezenbeek (Netherlands), Mario Raviglione (Switzerland)

Key components of effective and sustainable tuberculosis infection control program

Theory of airborne infections transmission. TB transmission in high DR-TB/HIV burden settings
Presenter/chair: Max Meis (Netherlands)


Wednesday, 02 December 2015

World Global TB Symposium

Adopting new policies
Chairs: Kitty van Weezenbeek, and Diana Weil

Friday, 04 December 2015

One pilot after another: How can we move up towards a sustainable scale-up of child lung health interventions?

TB CARE I project leading to the country-wide scale-up of symptom-based contact screening
Presenter/chair: Thien Huong Nguyen (Viet Nam)

Spelunking for treasure: searching for candidate biomarkers as prognostic indicators for treatment outcome
Coordinator: Kathleen England (Netherlands)

TB HIV epidemiology within the context of national TB prevalence surveys in Africa

Discussion: What do these survey results mean for TB and HIV programs in Africa?
Presenter/chair: Eveline Klinkenberg (Ethiopia)

Quality laboratory services and the impact and patient care
Coordinators: Alaine Umubyeyi Nyaruhirira (South Africa), Kathleen England (Netherlands)

Moving towards universal access to susceptibility testing: progress and challenges
Presenter/chair: Kathleen England (Netherlands)

Saturday, 05 December 2015

End TB, end MDR-TB
Coordinators: Agnes Gebhard (Netherlands), Fraser Douglas Wares (France)

Innovations to improve the TB/HIV patient experience: from diagnosis to treatment
Coordinator: Sara Massaut (Netherlands), Amy Piatek (USA)

Strengthening specimen referral and transport networks in resource-limited settings: a Nigerian pilot to improve diagnosis of TB in PLHIV
Presenter/chair: Sani Useni (Nigeria)

Taking stock of TB epidemiological assessments: experience, lessons learned and the way forward
Presenter/chair: Suzanne Verver (Netherlands)

Technical leadership in epidemiological assessments: global perspective
Presenter/chair: Eveline Klinkenberg (Ethiopia)

Achieving quality Xpert MTB/RIF use for rapid case detection
Coordinators: Alaine Umubyeyi Nyaruhirira (South Africa), Kathleen England (Netherlands)

Satellite symposium “Tuberculosis control in acute and chronic conflict”
Organizers: MSF

“Where do all the patients go?” –  Surveillance & patient follow up/ tracking in internal & external displacement situations & situations of access limitations due to security issues
Presenters: Job van Rest and Kathy Fiekert.

Sunday, 06 December 2015

The role of cost effectiveness in achieving the End TB Strategy
Presenter/chair: Michael Kimerling (Netherlands)

Innovative approach to improving access and quality of care for DR-TB: implementing the echo telehealth mode

Integration of ECHO for DR TB with an HIV ECHO program in Namibia
Nunurai Ruswa (Namibia)


Friday, 04 December 2015

Placing the patient at the center of care
Introduction of out-patient care for DS-/MDR-TB patients in Tajikistan.
(I. Leimane, O. Bobokhojaev, M. Makhmudova, Z. Abdulloeva, S. Verver)

Many paths to the same END TB strategy
Four degrees of separation: the influence of social and provider networks in the steps to diagnosis of active tuberculosis in urban Uganda.
(J.Sekandi, S. Zalwango, R. Kakaire, L. Martinez, A. Kizza, A. Ezeamama, N. Kiwanuka, C. Whalen)

The molecular basis of PZA resistance: from bench to bedside
Prevalence of common and rare Mycobacterium tuberculosis resistance-conferring mutations in Uganda. (W. Ssengooba, F. Cobelens, D. Lukoye, Gw Kasule, M. Joloba, B. de Jong)

Saturday, 05 December 2015

LBTI in high- and low-burden settings
Expected outcomes of serial testing with interferon-gamma release assays in North American health care workers: a Markov model. (A. Zwerling, M. Moses, A. Cattamanchi, C. Denkinger, N. Banaei, S. Kik, D. Dowdy, M. Pai)

From bench to treatment
In-patient wards as a source of missed pulmonary tuberculosis cases: a case study in Ethiopia. (D. Assefa Lemma, G.W. Desalgn, E. Klinkenberg)


Saturday, 05 December 2015

Rapid diagnosis the world over
Risk factors for loss to follow-up among DR-TB patients on second-line treatment in Kyrgyzstan. (A. Toktogonova, a. Estebesova, E. Kotysheva, S. Fedorova, E. Maliukova, N. Kurmanova, A. Ksdyrov, S. Verver)

Cost-effectiveness of the Ypert MTB/RIF assay for tuberculosis diagnosis in Brazil. (Mft Pinto. R. Steffen, F. Cobelens, S. van den Hof, A. Entringer, A. Trajman)

Modelling demonstrates that targeted use of Xpert MTB/RIF is a cost-effective and affordable option for tuberculosis diagnosis in Addis Ababa, Ethiopia. (A. Bika, Df. Adhana, D Assefa Lemma, E. Klinkenberg, S. Blanco. I Langley)

Sunday, 06 December 2015

  1. Tbilisi to Lima: a journey through TB treatment outcomes

Poor tuberculosis treatment outcomes in the district of Manhica, Mozambique, 2011-2012. (Al Garcia-Basteiro, D. Respeito, O. Joaquim Augusto, E Lopez Varela, C. Sacoor, I. Manhica, F. Cobelens, P. Alonso)

  1. When the tail wags the dog: drug resistance in TB programs

Why the current TB performance in Nigeria? Obvious but hidden deterrent factors. (M. Gidado, Sani Useni, J. Onazi, N. Peter, E. Mitchell, C. Fischer, G. Akang, R. Eneogu)

Projecting the impact of alternative drug susceptibility testing strategies on future TB drug resistance. (M. Fofana, S. Shrestha, G. Knight, T. Cohen, F. Cobelens, D. Dowdy)

Patient and provider delay in pulmonary tuberculosis patients: a cross-sectional study in Addis Ababa city, Ethiopia.

(D. Assefa Lemma, N. Kamp, E. Klinkenberg)

Clinical characteristics and diagnostic delay in spinal tuberculosis patients in The Netherlands. (D. Ijdema, C. Magis-Escurra, P. Horsting, C. Erkens, R. Aarnoutse, M. Boeree)

Patients suspecting TB are diagnosed earlier. (Simo Mutembo, J.M. Mutanga, J. Sekandi Nabbuye, B Mwangelwa, C. Kanene, K. Musokotwane, J. Chinyonga, C. Whalen)

Diagnostic barriers amond newly diagnosed pulmonary TB patients delay. (Ch. Zhumalieva, A. Estebesova, M. Ryspekova, D. Madybaeva, A. Tursynbayeva, N. Usenbaev, C. Kamerli, S. Verver)


Thursday, 03 December 2015

Pharmacovigilance for bedaquiline, delamanid and other TB drugs and regimens
Reflections on challenges, success and future directions on active pharmacovigilance for new TB drugs
A.Gebhard (Netherlands)